94 related articles for article (PubMed ID: 9106053)
1. Analysis of the imidazoacridinone C1311 by high-performance liquid chromatography.
Calabrese CR; Loadman PM
J Chromatogr B Biomed Sci Appl; 1997 Mar; 690(1-2):275-81. PubMed ID: 9106053
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and tissue distribution of the imidazoacridinone C1311 in tumour-bearing mice.
Calabrese CR; Bibby MC; Double JA; Loadman PM
Cancer Chemother Pharmacol; 1998; 42(5):379-85. PubMed ID: 9771952
[TBL] [Abstract][Full Text] [Related]
3. In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humans.
Calabrese CR; Loadman PM; Lim LS; Bibby MC; Double JA; Brown JE; Lamb JH
Drug Metab Dispos; 1999 Feb; 27(2):240-5. PubMed ID: 9929509
[TBL] [Abstract][Full Text] [Related]
4. Compatibility and stability of the novel anti-cancer agent C1311 in infusion devices and its in vitro biocompatibility.
den Brok MW; Nuijen B; Harms R; Buluran JN; Harvey MD; Grieshaber CK; Beijnen JH
J Oncol Pharm Pract; 2005 Mar; 11(1):13-9. PubMed ID: 16460599
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311.
Den Brok MW; Nuijen B; Kettenes-Van Den Bosch JJ; Van Steenbergen MJ; Buluran JN; Harvey MD; Grieshaber CK; Beijnen JH
PDA J Pharm Sci Technol; 2005; 59(5):285-97. PubMed ID: 16316064
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form.
den Brok MW; Nuijen B; Hillebrand MJ; Grieshaber CK; Harvey MD; Beijnen JH
J Pharm Biomed Anal; 2005 Sep; 39(1-2):46-53. PubMed ID: 15899571
[TBL] [Abstract][Full Text] [Related]
7. Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311.
Burger AM; Jenkins TC; Double JA; Bibby MC
Br J Cancer; 1999 Sep; 81(2):367-75. PubMed ID: 10496367
[TBL] [Abstract][Full Text] [Related]
8. Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection.
Zander SA; Beijnen JH; van Tellingen O
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jan; 913-914():129-36. PubMed ID: 23291288
[TBL] [Abstract][Full Text] [Related]
9. Cell growth inhibition, G2M cell cycle arrest and apoptosis induced by the imidazoacridinone C1311 in human tumour cell lines.
Zaffaroni N; De Marco C; Villa R; Riboldi S; Daidone MG; Double JA
Eur J Cancer; 2001 Oct; 37(15):1953-62. PubMed ID: 11576853
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer.
Burger AM; Double JA; Konopa J; Bibby MC
Br J Cancer; 1996 Nov; 74(9):1369-74. PubMed ID: 8912531
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of C1311 cytotoxic activity and interference with cell cycle progression in a panel of human solid tumour and leukaemia cell lines.
De Marco C; Zaffaroni N; Comijn E; Tesei A; Zoli W; Peters GJ
Int J Oncol; 2007 Oct; 31(4):907-13. PubMed ID: 17786324
[TBL] [Abstract][Full Text] [Related]
12. The binding of amsacrine to human plasma proteins.
Paxton JW; Jurlina JL; Foote SE
J Pharm Pharmacol; 1986 Jun; 38(6):432-8. PubMed ID: 2873219
[TBL] [Abstract][Full Text] [Related]
13. Quantitation of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in plasma by high-performance liquid chromatography.
Young D; Evans PC; Paxton JW
J Chromatogr; 1990 Jun; 528(2):385-94. PubMed ID: 2384576
[TBL] [Abstract][Full Text] [Related]
14. High-performance liquid chromatographic assay and preclinical pharmacological studies of pibenzimol (bisbenzimidazole).
Ames MM; Miller KJ; Moertel DM
J Chromatogr; 1985 May; 341(1):89-96. PubMed ID: 2410440
[TBL] [Abstract][Full Text] [Related]
15. High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates.
Lin F; Sherris D; Beijnen JH; Van Tellingen O
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Dec; 879(32):3823-31. PubMed ID: 22100549
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse.
Paxton JW; Young D; Evans SM; Kestell P; Robertson IG; Cornford EM
Cancer Chemother Pharmacol; 1992; 29(5):379-84. PubMed ID: 1551177
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a sensitive solid-phase-extraction and high-performance liquid chromatography assay for the bioreductive agent tirapazamine and its major metabolites in mouse and human plasma for pharmacokinetically guided dose escalation.
Robin H; Senan S; Workman P; Graham MA
Cancer Chemother Pharmacol; 1995; 36(3):266-70. PubMed ID: 7781150
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanism of the enzymatic oxidation investigated for imidazoacridinone antitumor drug, C-1311.
Mazerska Z; Sowiński P; Konopa J
Biochem Pharmacol; 2003 Nov; 66(9):1727-36. PubMed ID: 14563483
[TBL] [Abstract][Full Text] [Related]
19. Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection.
Lin F; Chandrasekaran G; de Gooijer MC; Beijnen JH; van Tellingen O
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Jul; 901():9-17. PubMed ID: 22727754
[TBL] [Abstract][Full Text] [Related]
20. Bio-analysis of vinorelbine by high-performance liquid chromatography with fluorescence detection.
van Tellingen O; Kuijpers A; Beijnen JH; Baselier MR; Burghouts JT; Nooyen WJ
J Chromatogr; 1992 Jan; 573(2):328-32. PubMed ID: 1601969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
